Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21035170 | 0.89 | CYP3A4 (0.32) | ALOX15CTNNB1TP53CYP3A4MEN1 | |
| SCHEMBL30442155 | 0.77 | CYP3A4 (0.34) | ALOX15TP53CYP3A4MEN1LMNA | |
| SCHEMBL21035809 | 0.77 | CYP3A4 (0.34) | ALOX15TP53CYP3A4MEN1LMNA | |
| SCHEMBL22614839 | 0.76 | CYP3A4 (0.30) | CYP3A4MAPT | |
| Acetic Acid SCHEMBL30441222 | 0.75 | — | — | |
| SCHEMBL21001305 | 0.74 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL14982984 | 0.73 | CYP3A4 (0.37) | TP53CYP3A4MEN1LMNAMAPT | |
| SCHEMBL5199434 | 0.70 | RIPK3 (0.33) | ALOX15CTNNB1CYP3A4MEN1LMNA | |
| SCHEMBL21001087 | 0.70 | CYP3A4 (0.33) | TP53CYP3A4MEN1LMNAMAPT | |
| SCHEMBL30441197 | 0.70 | CYP3A4 (0.33) | TP53CYP3A4MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066690-A1 | Spiro Compounds as Malodor Counteracting Ingredients | FIRMENICH SA (CH) | 2025-02-27 | — | — | US | claimed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | claimed |
| US-20230159853-A1 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | FIRMENICH SA (CH) | 2023-05-25 | — | — | US | claimed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | claimed |
| EP-3713609-A2 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | Firmenich SA (CH) | 2020-09-30 | — | — | EP | claimed |
| WO-2019101814-A2 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | FIRMENICH SA (CH) | 2019-05-31 | — | — | WO | claimed |
| EP-4707270-A2 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | Firmenich SA (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4632382-A2 | METHOD OF IDENTIFYING LAUNDRY MALODOR, MOLDY MALODOR AND/OR SWEAT MALODOR MODULATING COMPOUNDS | Firmenich SA (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-3713609-B1 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | FIRMENICH & CIE (CH) | 2025-08-06 | — | — | EP | disclosed |
| US-20250066690-A1 | Spiro Compounds as Malodor Counteracting Ingredients | FIRMENICH SA (CH) | 2025-02-27 | — | — | US | disclosed |
| US-12180434-B2 | Spiro compounds as malodor counteracting ingredients | FIRMENICH SA (CH) | 2024-12-31 | — | — | US | disclosed |
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | FIRMENICH SA (CH) | 2023-09-05 | — | — | US | disclosed |
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | FIRMENICH SA (CH) | 2023-09-05 | — | — | US | disclosed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | disclosed |
| EP-3713610-A2 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | Firmenich SA (CH) | 2020-09-30 | — | — | EP | disclosed |
| EP-3713609-A2 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | Firmenich SA (CH) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101814-A2 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | FIRMENICH SA (CH) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019101814-A2 | SPIRO COMPOUNDS AS MALODOR COUNTERACTING INGREDIENTS | FIRMENICH SA (CH) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019101821-A2 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019101821-A2 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | TAS2R8, TRPA1, TAS2R10 | ALOX15 514/4885CTNNB1 4151/4885TP53 4058/4885 |
| US-20250066690-A1 | Spiro Compounds as Malodor Counteracting Ingredients | LPO, SORD, FOXO1 | ALOX15 466/4885CTNNB1 1263/4885TP53 4339/4885 |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | ALOX15 514/4885CTNNB1 4151/4885TP53 4058/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | ALOX15 514/4885CTNNB1 4151/4885TP53 4058/4885 |
| US-12180434-B2 | Spiro compounds as malodor counteracting ingredients | LPO, SORD, FOXO1 | ALOX15 466/4885CTNNB1 1263/4885TP53 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.